Current Liabilities
Accounts Payable
Bristol-Myers Squibb Accounts Payable decreased by 16.6% to $3.58B in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 0.7%, from $3.60B to $3.58B. Over 5 years (FY 2020 to FY 2025), Accounts Payable shows an upward trend with a 5.7% CAGR.
Analysis
StatementBalance Sheet Statement
SectionCurrent Liabilities
CategoryEfficiency
SignalContext dependent
VolatilityModerate
First reportedQ3 2015
Last reportedQ4 2025
How to read this metric
An increase can indicate better credit terms or increased production volume, while a decrease might suggest faster payments or reduced purchasing.
Detailed definition
The amount of money a company owes to its suppliers and vendors for goods and services purchased on credit. In a large-s...
Peer comparison
Companies with significant supply chain leverage often maintain high payables to maximize their own cash-on-hand.
Metric ID:
accounts_payableHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $3.61B | $2.70B | $2.95B | $2.94B | $2.88B | $2.60B | $3.04B | $3.19B | $3.07B | $2.81B | $3.26B | $3.54B | $3.75B | $3.47B | $3.60B | $4.00B | $5.43B | $4.29B | $3.58B |
| QoQ Change | — | -25.3% | +9.4% | -0.2% | -2.1% | -10.0% | +17.1% | +5.1% | -3.9% | -8.3% | +15.9% | +8.6% | +6.0% | -7.5% | +3.8% | +11.1% | +35.6% | -21.0% | -16.6% |
| YoY Change | — | — | — | — | -20.1% | -3.7% | +3.1% | +8.5% | +6.5% | +8.4% | +7.2% | +10.8% | +22.2% | +23.3% | +10.5% | +13.1% | +44.7% | +23.6% | -0.7% |
Range$2.60B – $5.43B
CAGR-0.2%
Avg YoY Growth+10.5%
Median YoY Growth+8.5%
Current Streak2 quarters decline
Accounts Payable at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's accounts payable?
- Bristol-Myers Squibb (BMY) reported accounts payable of $3.58B in Q4 2025.
- How has Bristol-Myers Squibb's accounts payable changed year-over-year?
- Bristol-Myers Squibb's accounts payable decreased by 0.7% year-over-year, from $3.60B to $3.58B.
- What is the long-term trend for Bristol-Myers Squibb's accounts payable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts payable has grown at a 5.7% compound annual growth rate (CAGR), from $2.71B to $3.58B.
- What does accounts payable mean?
- The total amount of money the company owes to its suppliers for items it has already received.